Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Protegrin-1 (PG-1) is a potent, cationic 18-amino acid antimicrobial peptide (AMP) belonging to the cathelicidin family, originally isolated from porcine leukocytes. It adopts a stable β-hairpin structure stabilized by two internal disulfide bonds. PG-1 exhibits broad-spectrum microbicidal activity against Gram-positive and Gram-negative bacteria (including multidrug-resistant strains like MRSA and *Acinetobacter baumannii*), fungi, and certain enveloped viruses. Its primary mechanism of action involves binding to and disrupting microbial cell membranes through pore formation, leading to rapid lysis and cell death. Beyond its direct microbicidal effects, PG-1 possesses immunomodulatory properties, including the ability to temper inflammatory responses by inhibiting the NF-κB and MAPK signaling pathways. It has also been investigated for its potential to inhibit the Dengue virus NS2B-NS3 serine protease and for its anticancer activity against tumors such as glioblastoma. Although highly effective, the clinical development of the natural PG-1 peptide has been hindered by its toxicity to mammalian cells, particularly its hemolytic activity, which has led to the development of synthetic analogs with improved safety profiles.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on protegrin-1.